# Precursor Cell Lymphoblastic Leukemia-Lymphoma: 188 new

Updated November 6, 2026.

188 clinical studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma were first posted on ClinicalTrials.gov from November 26, 2024 to November 6, 2026; 22 have an industry sponsor and 158 are recruiting or about to. The newest, NCT07923071, was posted on November 6, 2026: A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and... (Syndax Pharmaceuticals).

## The full list

New Precursor Cell Lymphoblastic Leukemia-Lymphoma clinical trials: 188 rows for $9.40, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/precursor-cell-lymphoblastic-leukemia-lymphoma

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 188
- Industry sponsored: 22
- Recruiting or not yet: 158
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 188, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 5, 2026 | NCT07919470 | Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT | Peking University People's Hospital | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia, Hematopoietic Stem Cell Transplantation | 180 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919470) |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| October 20, 2026 | NCT07884474 | Feasibility and Acceptability of Remote Saliva Collection | St. Jude Children's Research Hospital | Observational | Recruiting | Survivors of Childhood Cancer, Acute Lymphoblastic Leukemia, Childhood | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884474) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | GUSTAVO SALGUERO | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 20, 2026 | NCT07882069 | Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia | Selcuk University | Not applicable | Completed | Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent, Resilience... | 70 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882069) |
| October 5, 2026 | NCT07858214 | Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort | Head Diagnostics | Observational | Enrolling by invitation | All Conditions, All | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858214) |
| October 5, 2026 | NCT07856758 | 2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy | M.D. Anderson Cancer Center | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856758) |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| September 10, 2026 | NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | University of West Attica | Not applicable | Active not recruiting | Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant, Psychological Trauma, Neoplasms, Hematological Malignancies... | 80 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814170) |
| September 10, 2026 | NCT07813208 | Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival | The Children's Hospital of Zhejiang University School of Medicine | Observational | Recruiting | Acute Lymphoblastic Leukemia, Pediatric | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813208) |
| September 9, 2026 | NCT07809984 | Prevention of Oral Mucositis in Adults in With Hematologic Malignancy | Wake Forest University Health Sciences | Not applicable | Not yet recruiting | Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis | 206 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809984) |
| August 31, 2026 | NCT07795099 | A Single-center, Prospective, Exploratory Clinical Study | LanZhou University | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795099) |
| August 25, 2026 | NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Enrolling by invitation | Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory... | 13 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784309) |
| August 21, 2026 | NCT07780123 | Nurture by Nature Feasibility Study | Ina Olmer Specht | Not applicable | Recruiting | Nature, Human, Pediatric ALL, Well-Being, Psychological | 127 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780123) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| August 13, 2026 | NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | Observational | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma, Multiple Myeloma, Chronic... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763054) |
| August 7, 2026 | NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Observational | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751588) |
| August 3, 2026 | NCT07742891 | ReSeT in ALL 2: A Randomized, Controlled Pilot Trial Testing an Optimized, Multi-component Mobile Health Intervention to Reduce Sedentary... | Children's Hospital Los Angeles | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia (ALL), Sedentary Behavior / Physical Inactivity, Cardiometabolic Health | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742891) |
| July 17, 2026 | NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic... | Ossium Health, Inc. | Not applicable | Not yet recruiting | Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic... | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710781) |
| July 15, 2026 | NCT07705178 | More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL... | University of Erlangen-Nürnberg Medical School | Not applicable | Recruiting | Acute Lymphatic Leukemia, Lymphoma | 180 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705178) |
| July 10, 2026 | NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia | Zhujiang Hospital | Early phase 1 | Not yet recruiting | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory... | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696481) |
| July 10, 2026 | NCT07695012 | CAR-T Cell Therapy for ALL | Dr. Zaineb Akram | Early phase 1 | Recruiting | Relapsed Acute Lymphoblastic Leukemia (ALL) | 10 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695012) |
| July 6, 2026 | NCT07684131 | EWALL-PH OBSERVARTORY 2022 | Versailles Hospital | Observational | Recruiting | Acute Lymphoblastic Leukemia | 100 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684131) |
| June 12, 2026 | NCT07644351 | A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients | Novartis Pharmaceuticals | Observational | Completed | Acute Lymphoblastic Leukemia | 37 | Australia, Canada, China, France, Israel, Italy, Netherlands, Pakistan, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644351) |
| June 9, 2026 | NCT07634653 | Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL) | UNC Lineberger Comprehensive Cancer Center | Not applicable | Recruiting | Leukemia, Acute Leukemia, Acute Lymphoid Leukemia, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634653) |
| June 8, 2026 | NCT07632014 | CAYA Cancer Prospective Cohort Study | Resonance, Inc. | Observational | Recruiting | Cancer, Pediatric Cancer, Lymphoblastic Lymphoma (LBL), Acute Lymphoblastic Leukemia (ALL) | 6,000 | Armenia, Egypt, El Salvador, Guatemala, Honduras | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632014) |
| June 3, 2026 | NCT07623655 | CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia | Gruppo Italiano Malattie EMatologiche dell'Adulto | Observational | Not yet recruiting | Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia | 107 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623655) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| May 29, 2026 | NCT07614022 | A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute... | Wake Forest University Health Sciences | Phase 1 | Recruiting | Philadelphia Positive Acute Lymphoblastic Leukemia | 26 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614022) |
| May 19, 2026 | NCT07597590 | Digital Patient-Reported Assessment in Older Adults With Acute Leukemia | Fundación para la Investigación Biosanitaria del Principado de Asturias | Not applicable | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 20 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597590) |
| May 14, 2026 | NCT07586618 | First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic... | Allterum Therapeutics, Inc | Phase 1 | Recruiting | Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586618) |
| May 13, 2026 | NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | Shenzhen University General Hospital | Phase 1/2 | Recruiting | B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584889) |
| May 11, 2026 | NCT07577531 | Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia/Lymphoma in First Complete Remission | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Observational | Not yet recruiting | T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577531) |
| May 8, 2026 | NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell, Conditioning Therapy, SHR2554... | 180 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575412) |
| May 7, 2026 | NCT07573111 | Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem... | Laguna Biotherapeutics, Inc. | Phase 1 | Recruiting | Acute Leukemia, Myelodysplastic Syndrome | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573111) |
| May 7, 2026 | NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing... | National Cancer Institute (NCI) | Phase 1 | Recruiting | B-All, Acute Lymphoblastic Leukemia | 57 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572136) |
| May 5, 2026 | NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin... | 71 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566377) |
| May 4, 2026 | NCT07565220 | Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic... | Sawa Ito, MD | Phase 1 | Recruiting | Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS)... | 48 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565220) |
| May 1, 2026 | NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell, Conditioning Therapy, SHR2554... | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562568) |
| April 14, 2026 | NCT07529223 | Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblastic Leukemia. | Centre Hospitalier Universitaire de Nice | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia ALL | 20 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529223) |
| April 13, 2026 | NCT07522905 | Virtual Buddy Movement Therapy for Psychomotor and Social Development in Pediatric Oncology Patients in Remission | Comenius University | Not applicable | Recruiting | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 | Slovakia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522905) |
| April 8, 2026 | NCT07518654 | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or... | Michel Duval | Phase 1 | Not yet recruiting | Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic, Leukaemia... | 12 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518654) |
| April 8, 2026 | NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | Dana-Farber Cancer Institute | Not applicable | Not yet recruiting | Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma, Acute... | 143 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516353) |
| April 7, 2026 | NCT07515430 | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia | Sun Yat-sen University | Observational | Enrolling by invitation | Acute Lymphoblastic Leukemia | 138 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515430) |
| April 3, 2026 | NCT07509385 | The Role of Serum Cytokines IL\_17 A and IL\_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt | Assiut University | Observational | Not yet recruiting | Acute Lymphoblastic Leukemia, B-Cell | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509385) |
| March 30, 2026 | NCT07499349 | Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment... | Aarhus University Hospital | Observational | Recruiting | Acute Lymphoblastic Leukemia | 475 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499349) |
| March 30, 2026 | NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | National Cancer Institute (NCI) | Not applicable | Enrolling by invitation | Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma... | 136 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499128) |
| March 27, 2026 | NCT07498465 | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With... | Children's Oncology Group | Phase 1 | Withdrawn | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid... | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498465) |
| March 27, 2026 | NCT07495631 | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Recruiting | Acute Lymphoblastic Leukemia, Adult | 43 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495631) |
| March 19, 2026 | NCT07483749 | HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors | The Children's Hospital of Zhejiang University School of Medicine | Observational | Not yet recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia, Pediatric | 400 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483749) |
| March 19, 2026 | NCT07483476 | Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia | Assistance Publique - Hôpitaux de Paris | Observational | Recruiting | Acute Lymphoblastic Leukemia ALL | 205 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483476) |
| March 18, 2026 | NCT07479927 | Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or... | Hospital Universitario La Paz | Not applicable | Recruiting | Acute Lymphoblastic Leukemia | 40 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479927) |
| March 13, 2026 | NCT07469592 | eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation | University of Miami | Not applicable | Recruiting | Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic... | 165 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469592) |
| March 10, 2026 | NCT07462299 | NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy | The Children's Hospital of Zhejiang University School of Medicine | Not applicable | Not yet recruiting | Childhood Acute Lymphoblastic Leukemia | 110 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462299) |
| March 6, 2026 | NCT07454226 | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Recruiting | Ph-Like, Acute Lymphoblastic Leukemia | 92 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454226) |
| March 5, 2026 | NCT07451743 | Are Clinical Outcomes Unchanged by ALL Fixation at 0° or 30° of Knee Flexion in Combined ACL-ALL Reconstruction? Despite Numerous Technical... | ASL Lecce | Not applicable | Not yet recruiting | Anterior Cruciate Ligament Rupture | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451743) |
| March 2, 2026 | NCT07443592 | Treatment for Ph-negative ALL for Adults up to 65 Years | PETHEMA Foundation | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia | 330 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443592) |
| February 23, 2026 | NCT07428486 | A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute... | M.D. Anderson Cancer Center | Phase 1 | Withdrawn | Phase I, FLAG Chemotherapy, Lisaftoclax, Pelcitoclax, Relapsed/Refractory, Lymphoblastic Leukemia Acute | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428486) |
| February 11, 2026 | NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC... | Azienda Ospedaliero-Universitaria di Parma | Not applicable | Recruiting | Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma, Pancreatic Cancer, Bladder Cancer... | 300 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403630) |
| February 10, 2026 | NCT07400029 | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400029) |
| February 4, 2026 | NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class... | Novartis Pharmaceuticals | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive... | 50 | Australia, Israel, South Korea, Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387926) |
| January 28, 2026 | NCT07374315 | Weight Gain in Pediatric Leukemia Survivors | Washington University School of Medicine | Not applicable | Not yet recruiting | Leukemia, Pediatric Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia in Remission, Pediatric Obesity | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374315) |
| January 28, 2026 | NCT07371533 | Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) | Shanxi Bethune Hospital | Not applicable | Not yet recruiting | Acute Lymphocytic Leukemia | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371533) |
| January 27, 2026 | NCT07371403 | MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia | King Hussein Cancer Center | Not applicable | Recruiting | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Refractory, Acute... | 12 | Jordan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371403) |
| January 26, 2026 | NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After... | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2/3 | Recruiting | Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute... | 64 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366801) |
| January 22, 2026 | NCT07361029 | CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia | King Faisal Specialist Hospital & Research Center | Phase 1 | Recruiting | Relapsed Refractory Acute Lymphoblastic Leukemia | 24 | Saudi Arabia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361029) |
| January 21, 2026 | NCT07356960 | Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world | Gruppo Italiano Malattie EMatologiche dell'Adulto | Observational | Not yet recruiting | Acute Lymphobkastic Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 103 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356960) |
| January 21, 2026 | NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia... | 52 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356154) |
| January 16, 2026 | NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | Orca Biosystems, Inc. | Not applicable | Available | Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndrome, Mixed Phenotype... | Not listed | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07346105) |
| January 9, 2026 | NCT07328503 | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, B-All | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328503) |
| January 8, 2026 | NCT07327138 | Children's Laughter and Fun Yoga as Adjunctive Pain Relief Following Chemotherapy. | Bahaa Bou Dargham | Not applicable | Recruiting | Acute Lymphoblastic Leukemia ALL | 60 | Lebanon | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07327138) |
| January 8, 2026 | NCT07326930 | Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia | The Hong Kong Polytechnic University | Observational | Recruiting | Acute Lymphoblastic Leukemia ALL | 173 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326930) |
| January 8, 2026 | NCT07325305 | Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and... | Murdoch Childrens Research Institute | Not applicable | Recruiting | Sarcopenia, Acute Lymphoblastic Leukemia | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325305) |
| January 6, 2026 | NCT07320534 | Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase | Gadjah Mada University | Phase 4 | Terminated | Neutropenic Fever, Acute Lymphoblastic Leukemia | 49 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07320534) |
| January 6, 2026 | NCT07319481 | Preliminary Effectiveness and Feasibility of Transcutaneous Acupoints Electrical Stimulation on Chemotherapy-induced Peripheral Neuropathy... | The Hong Kong Polytechnic University | Not applicable | Not yet recruiting | Chemotherapy Induced Peripheral Neuropathy (CIPN) | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07319481) |
| January 2, 2026 | NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | Washington University School of Medicine | Observational | Recruiting | Acute Lymphoblastic Leukemia | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07313592) |
| December 31, 2025 | NCT07312630 | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Recruiting | Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | 19 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312630) |
| December 24, 2025 | NCT07301424 | Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | University of Alberta | Phase 2 | Not yet recruiting | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | 80 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301424) |
| December 24, 2025 | NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | Ruijin Hospital | Phase 2 | Not yet recruiting | Acute Lymphoblastic Leukemia | 23 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301138) |
| December 22, 2025 | NCT07297914 | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL | Bambino Gesù Hospital and Research Institute | Phase 2/3 | Recruiting | Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease | 1,000 | Austria, Czechia, Denmark, Finland, France, Germany, Italy, Norway, Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297914) |
| December 22, 2025 | NCT07295951 | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia | Janssen Research & Development, LLC | Phase 1 | Completed | Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia | 6 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295951) |
| December 16, 2025 | NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284927) |
| December 16, 2025 | NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283640) |
| December 2, 2025 | NCT07258043 | Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia | Hospital General de Mexico | Observational | Recruiting | Acute Lymphobkastic Leukemia, Leukemia, Overall Survival | 45 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258043) |
| December 2, 2025 | NCT07257419 | CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for... | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257419) |
| November 28, 2025 | NCT07254793 | Prophylactic DLI-X for Leukemia Relapse After HCT | University of Arizona | Phase 1 | Recruiting | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome... | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254793) |
| November 24, 2025 | NCT07246213 | CAYA Cancer Retrospective Cohort Study | Resonance, Inc. | Observational | Recruiting | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer, Childhood Cancers, Acute... | 18,000 | Armenia, Egypt, El Salvador, Guatemala, Honduras, Tanzania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246213) |
| November 20, 2025 | NCT07238907 | A Multi-center Retrospective Study of INO Treating B-ALL | Ruijin Hospital | Observational | Active not recruiting | Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin, Venetoclax | 102 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238907) |
| November 14, 2025 | NCT07228741 | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Obesity | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228741) |
| November 12, 2025 | NCT07227584 | ALL Backbone in AYAs | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia... | 67 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227584) |
| November 4, 2025 | NCT07224100 | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute... | University of Washington | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With... | 33 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224100) |
| October 31, 2025 | NCT07223190 | A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic... | Amgen | Phase 3 | Not yet recruiting | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | 560 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223190) |
| October 28, 2025 | NCT07221656 | Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration | Mayo Clinic | Observational | Not yet recruiting | Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221656) |
| October 2, 2025 | NCT07203742 | The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment | Ege University | Not applicable | Recruiting | Acute Lymphoblastic Leukemia, Childhood Acute Leukemia, Acute Myeloblastic Leukaemia | 60 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203742) |
| October 2, 2025 | NCT07203352 | Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL | Nanfang Hospital, Southern Medical University | Phase 3 | Recruiting | Acute Lymphoblastic Leukemia | 154 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203352) |
| September 25, 2025 | NCT07192237 | Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell... | M.D. Anderson Cancer Center | Phase 2 | Suspended | Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192237) |
| September 24, 2025 | NCT07191119 | Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia | St. Jude Children's Research Hospital | Not applicable | Recruiting | Survivor of Childhood Cancer, Insomnia, Acute Lymphoblastic Leukemia (ALL) | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07191119) |
| September 17, 2025 | NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178912) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| St. Jude Children's Research Hospital | 9 | October 20, 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | 9 | August 25, 2026 |
| M.D. Anderson Cancer Center | 6 | October 5, 2026 |
| First Affiliated Hospital of Zhejiang University | 6 | June 4, 2025 |
| The First Affiliated Hospital of Soochow University | 4 | May 8, 2026 |
| National Cancer Institute (NCI) | 4 | May 7, 2026 |
| City of Hope Medical Center | 4 | June 13, 2025 |
| The Children's Hospital of Zhejiang University School of Medicine | 3 | September 10, 2026 |
| Novartis Pharmaceuticals | 3 | June 12, 2026 |
| Memorial Sloan Kettering Cancer Center | 3 | May 5, 2026 |
| Assiut University | 3 | April 3, 2026 |
| Shanxi Bethune Hospital | 3 | January 28, 2026 |
| Ruijin Hospital | 3 | December 24, 2025 |
| Hospital Universitario Dr. Jose E. Gonzalez | 2 | October 22, 2026 |
| Wake Forest University Health Sciences | 2 | September 9, 2026 |
| Ossium Health, Inc. | 2 | July 17, 2026 |
| Zhujiang Hospital | 2 | July 10, 2026 |
| Resonance, Inc. | 2 | June 8, 2026 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 2 | June 3, 2026 |
| Dana-Farber Cancer Institute | 2 | April 8, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 60 | November 5, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 34 | October 20, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 30 | September 14, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 29 | November 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 14 | October 22, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 8 | January 26, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 5 | July 10, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 5 | January 6, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 3 | October 31, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 61 | October 23, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 44 | November 5, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 7 | July 6, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 7 | June 12, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 7 | June 12, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 7 | June 8, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 6 | June 12, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 6 | June 12, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 5 | October 20, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 5 | June 12, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 5 | September 3, 2025 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 4 | August 21, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 4 | July 15, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 4 | January 26, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 3 | October 22, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 3 | February 4, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 3 | February 4, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 2 | July 10, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 2 | June 12, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 2 | June 12, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 2 | June 12, 2026 |
| [Armenia](https://specstream.ai/data/clinical-trials/country/armenia) | 2 | June 8, 2026 |
| El Salvador | 2 | June 8, 2026 |
| [Guatemala](https://specstream.ai/data/clinical-trials/country/guatemala) | 2 | June 8, 2026 |
| [Honduras](https://specstream.ai/data/clinical-trials/country/honduras) | 2 | June 8, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).